

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hansoh Pharmaceutical Group Company Limited

翰森製藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3692)

RESCHEDULE OF DATES FOR INTERIM DIVIDEND FOR THE SIX MONTHS ENDED JUNE 30, 2025 DUE TO WEATHER CONDITIONS

Reference is made to the interim results announcement for the six months ended June 30, 2025 of Hansoh Pharmaceutical Group Company Limited (the “**Company**”) dated August 18, 2025 (the “**Interim Results Announcement**”) and 2025 interim report published on September 22, 2025 (“**Interim Report**”) in relation to interim dividend and closure of register of members.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company announces that due to unstable weather condition, the Company decided to reschedule related dates as follows:

	Original date(s)	Rescheduled date(s)
Latest time to lodge transfer documents for registration with share registrar for determining entitlement to the dividend	September 23, 2025 16:30	September 25, 2025 16:30
Book close period	September 24, 2025 to September 25, 2025 (both dates inclusive)	September 26, 2025 to September 29, 2025 (both dates inclusive)
Record date	September 25, 2025	September 29, 2025

Saved as disclosed above, the Company confirms that the payment date of interim dividend remains on October 30, 2025 and all other information contained in the Interim Results Announcement and the Interim Report remain the same.

By Order of the Board
Hansoh Pharmaceutical Group Company Limited
Zhong Huijuan
Chairlady

Hong Kong, September 23, 2025

As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive Director, Ms. Sun Yuan and Dr. Lyu Aifeng as executive Directors, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai and Ms. Yang Dongtao as independent non-executive Directors.